Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 90Neoplasms, Plasma Cell 28Central Nervous System Neoplasms 11Recurrence 10Glioblastoma 10Neoplasms 9Carcinoma, Hepatocellular 9Brain Neoplasms 9Gliosarcoma 8Melanoma 6Lung Neoplasms 6Leukemia 6Glioma 6Carcinoma, Non-Small-Cell Lung 6Waldenstrom Macroglobulinemia 5Prostatic Neoplasms 5Lymphoma, Mantle-Cell 5Myeloproliferative Disorders 4Lymphoma, B-Cell, Marginal Zone 4Leukemia, Lymphocytic, Chronic, B-Cell 4Immunoglobulin Light-chain Amyloidosis 4Colorectal Neoplasms 4Carcinoma, Renal Cell 4Astrocytoma 4Uveal Melanoma 3Oligodendroglioma 3Neuroblastoma 3Myelodysplastic-Myeloproliferative Diseases 3Myelodysplastic Syndromes 3Medulloblastoma 3

Interventions

fludarabine phosphate 26Etoposide 23Peripheral Blood Stem Cell Transplantation 22pegaspargase 21Whole-Body Irradiation 21Mycophenolic Acid 20Cyclophosphamide 19Busulfan 17Gemcitabine 16Dexamethasone 16Tacrolimus 15Methotrexate 15Cyclosporine 12Radiotherapy 11Antilymphocyte Serum 11Melphalan 8Asparaginase 8Rituximab 7Oxaliplatin 7Flow Cytometry 6Therapeutics 5Lenalidomide 5Bortezomib 5thymoglobulin 4spartalizumab 4Transplantation 4Polymerase Chain Reaction 4Panobinostat 4Methylprednisolone 4Everolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Lymphoma, Extranodal NK-T-Cell × Thalidomide × Clear all
NCT02085655 2021-03-15

PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Sun Yat-sen University

Phase 3 Unknown
264 enrolled
Lymphoid

Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡